When it comes to therapeutics, new is good, but what we really need are breakthrough drugs and products
Blood · 19.11.2026 · 148 (21) · 2553-2555
DOI: 10.1182/blood.2026035564 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, erschienen am 19.11.2026. Verfasst von Andrew W. Roberts. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Rather than incremental improvements over existing therapies, the greatest need in hematology is for breakthrough therapeutic agents that address major unmet clinical needs and transform treatment paradigms. In this editorial, Blood Editor-in-Chief Andrew W. Roberts calls for hematologists to prioritize the development and rigorous evaluation of innovative therapies, including optimizing their dose, duration, safety, and applications, while redirecting resources from less impactful drug development toward evidence-based advances that meaningfully improve patient outcomes.
Zitieren
APA
Roberts, A. W. (2026). When it comes to therapeutics, new is good, but what we really need are breakthrough drugs and products. Blood, 148(21), 2553-2555. https://doi.org/10.1182/blood.2026035564
Vancouver
Roberts AW. When it comes to therapeutics, new is good, but what we really need are breakthrough drugs and products. Blood. 2026;148(21):2553-2555. doi:10.1182/blood.2026035564
BibTeX
@article{Roberts2026,
author = {Roberts, Andrew W.},
title = {When it comes to therapeutics, new is good, but what we really need are breakthrough drugs and products},
journal = {Blood},
year = {2026},
volume = {148},
number = {21},
pages = {2553--2555},
doi = {10.1182/blood.2026035564}
}
EUVIMED